Senior insider sale
Chief Medical Officer at TRAVERE THERAPEUTICS, INC. — senior position signals high conviction
$1.35M
30.41K shares
What this filing means
INRIG JULA plans to sell 30.41K shares of TRAVERE THERAPEUTICS, INC. valued at approximately $1.35M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 5/5/2026ACC: 0001193125-26-207080
Officer· Chief Medical Officer
Since Jan 2022
30.41K
Shares to sell
$1.35M
Approx. market value
2.17K
Acquired (3 months)
1
Planned
3 completed
Securities Acquired — Last 3 Months1
Performance Restricted Stock Unit Vesting
Compensation
5/4/2026
2.17KTotal acquired2.17K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
5/4/2026 | Performance Restricted Stock Unit Vesting Compensation | 2.17K | — |
| Total | 2.17K | ||
Planned & Completed Dispositions4
Completed
—Completed
Units to sell
20K
Market value
$900.0K
5/4/2026
—Completed
Units to sell
1.02K
Market value
$43.4K
4/15/2026
—Completed
Units to sell
7.21K
Market value
$302.5K
4/14/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
2.17K
Market value
$101.4K
5/5/2026
Total
Units
30.41K
Value
$1.35M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
5/4/2026 | 20K | $900.0K | — | Completed |
4/15/2026 | 1.02K | $43.4K | — | Completed |
4/14/2026 | 7.21K | $302.5K | — | Completed |
| Planned — Approximate Date | ||||
5/5/2026 | 2.17K | $101.4K | NASDAQ | Planned |
| Total | 30.41K | $1.35M | ||